NEXTO NEXTO
Resultados de pesquisa
Veja todos os resultados
  • Acessar
    Entrar
    Cadastrar
    Pesquisar
    Night Mode

Pesquisar

Conheça novas pessoas, crie conexões e faça novos amigos

  • Feed de notícias
  • ECOSYSTEM
  • EXPLORAR
  • Páginas
  • Grupos
  • Eventos
  • Blogs
  • Publicações
  • Blogs
  • Usuários
  • Páginas
  • Grupos
  • Eventos
  • Shreya Patil adicionou um novo artigo Outro
    2025-12-15 07:41:57 -
    Breast Cancer Diagnostics Market Size, Share, Demand, Rising Trends, Growth and Competitors Analysis
    Breast Cancer Diagnostics Market By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others)...
    0 Comentários 0 Compartilhamentos 288 Visualizações 0 Anterior
    Faça o login para curtir, compartilhar e comentar!
  • Shreya Patil adicionou um novo artigo Outro
    2025-12-22 07:14:16 -
    Breast Cancer Diagnostics Market Size, Share, Trends, Key Drivers, Growth Opportunities and Competitive Outlook
    Breast Cancer Diagnostics Market By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others) Industry...
    0 Comentários 0 Compartilhamentos 242 Visualizações 0 Anterior
    Faça o login para curtir, compartilhar e comentar!
  • Sai Datam adicionou um novo artigo Health
    2025-09-18 06:54:42 -
    ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Emerging Opportunities
    ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size The ESR1 Mutated Metastatic Breast Cancer Diagnostics Market is an emerging, clinically important segment of oncology diagnostics driven by the need to detect acquired resistance to endocrine therapy in hormone-receptor (HR+) metastatic breast cancer. Market estimates place the diagnostics segment at roughly US$ 60–65 million...
    0 Comentários 0 Compartilhamentos 790 Visualizações 0 Anterior
    Faça o login para curtir, compartilhar e comentar!
© 2026 NEXTO Portuguese (Brazil)
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
Sobre Termos Privacidade Community Guidelines Tokenomics Roadmap & Updates Security & Safety Tips FAQ Cookie Policy Fale conosco Diretório